Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

Tamer Khashab, Fredrick Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter McLaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Younes, Lei Feng, Francisco Vega, Larry W. Kwak, Felipe Samaniego

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences